TGFBI Modulates Tumour Hypoxia and Promotes Breast Cancer Metastasis

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2020 Oct 20

PMID 33080107

Citations 32

Authors

Flavia Fico

Albert Santamaria-Martinez

Affiliations

Soon will be listed here.

Abstract

Breast cancer metastasis is a complex process that depends not only on intrinsic characteristics of metastatic stem cells, but also on the particular microenvironment that supports their growth and modulates the plasticity of the system. In search for microenvironmental factors supporting cancer stem cell (CSC) growth and tumour progression to metastasis, we here investigated the role of the matricellular protein transforming growth factor beta induced (TGFBI) in breast cancer. We crossed the MMTV-PyMT model of mammary gland tumorigenesis with a Tgfbi mouse and studied the CSC content of the tumours. We performed RNAseq on wt and ko tumours, and analysed the tumour vasculature and the immune compartment by IHC and FACS. The source of TGFBI expression was determined by qPCR and by bone marrow transplantation experiments. Finally, we performed in silico analyses using the METABRIC cohort to assess the potential prognostic value of TGFBI. We observed that deletion of Tgfbi led to a dramatic decrease in CSC content and lung metastasis. Our results show that lack of TGFBI resulted in tumour vessel normalisation, with improved vessel perfusion and decreased hypoxia, a major factor controlling CSCs and metastasis. Furthermore, human data mining in a cohort of breast cancer patients showed that higher expression of TGFBI correlates with poor prognosis and is associated with the more aggressive subtypes of breast cancer. Overall, these data reveal a novel biological mechanism controlling metastasis that could potentially be exploited to improve the efficacy and delivery of chemotherapeutic agents in breast cancer.

Citing Articles

Regulation of PHD2 by HIF-1α in Erythroid Cells: Insights into Erythropoiesis Under Hypoxia.

Wang S, Xu Q, Liu W, Zhang N, Qi Y, Tang F Int J Mol Sci. 2025; 26(2.

PMID: 39859474 PMC: 11765976. DOI: 10.3390/ijms26020762.

Integrated analysis of bulk and single-cell RNA sequencing reveals the impact of nicotinamide and tryptophan metabolism on glioma prognosis and immunotherapy sensitivity.

Wang S, Gao S, Lin S, Fang X, Zhang H, Qiu M BMC Neurol. 2024; 24(1):419.

PMID: 39468708 PMC: 11514892. DOI: 10.1186/s12883-024-03924-5.

TGFBI promotes proliferation and epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR/HIF-1α pathway.

Zhan S, Bai X, Zhao Y, Tuoheti K, Yisha Z, Zuo Y Cancer Cell Int. 2024; 24(1):265.

PMID: 39068456 PMC: 11282683. DOI: 10.1186/s12935-024-03454-7.

Effect of cellular senescence on the response of human peritoneal mesothelial cells to TGF-β.

Kawka E, Herzog R, Rucinski M, Malinska A, Unterwurzacher M, Sacnun J Sci Rep. 2024; 14(1):12744.

PMID: 38830931 PMC: 11148043. DOI: 10.1038/s41598-024-63250-1.

Integrated Analysis Identified TGFBI as a Biomarker of Disease Severity and Prognosis Correlated with Immune Infiltrates in Patients with Sepsis.

Shi M, Wei Y, Guo R, Luo F J Inflamm Res. 2024; 17:2285-2298.

PMID: 38645878 PMC: 11027929. DOI: 10.2147/JIR.S456132.

References

Brooks M, Burness M, Wicha M . Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. Cell Stem Cell. 2015; 17(3):260-71. PMC: 4560840. DOI: 10.1016/j.stem.2015.08.014. View

Hu Y, Smyth G . ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009; 347(1-2):70-8. DOI: 10.1016/j.jim.2009.06.008. View

Ahmed A, Mills A, Ibrahim A, Temple J, Blenkiron C, Vias M . The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell. 2007; 12(6):514-27. PMC: 2148463. DOI: 10.1016/j.ccr.2007.11.014. View

Hashimoto K, Noshiro M, Ohno S, Kawamoto T, Satakeda H, Akagawa Y . Characterization of a cartilage-derived 66-kDa protein (RGD-CAP/beta ig-h3) that binds to collagen. Biochim Biophys Acta. 1997; 1355(3):303-14. DOI: 10.1016/s0167-4889(96)00147-4. View

Martinez F, Gordon S, Locati M, Mantovani A . Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006; 177(10):7303-11. DOI: 10.4049/jimmunol.177.10.7303. View

Billings P, Whitbeck J, Adams C, Abrams W, Cohen A, Engelsberg B . The transforming growth factor-beta-inducible matrix protein (beta)ig-h3 interacts with fibronectin. J Biol Chem. 2002; 277(31):28003-9. DOI: 10.1074/jbc.M106837200. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Dobin A, Davis C, Schlesinger F, Drenkow J, Zaleski C, Jha S . STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2012; 29(1):15-21. PMC: 3530905. DOI: 10.1093/bioinformatics/bts635. View

Nummela P, Lammi J, Soikkeli J, Saksela O, Laakkonen P, Holtta E . Transforming growth factor beta-induced (TGFBI) is an anti-adhesive protein regulating the invasive growth of melanoma cells. Am J Pathol. 2012; 180(4):1663-74. DOI: 10.1016/j.ajpath.2011.12.035. View

10.

Xiang L, Gilkes D, Hu H, Takano N, Luo W, Lu H . Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. Oncotarget. 2015; 5(24):12509-27. PMC: 4350363. DOI: 10.18632/oncotarget.2997. View

11.

Peng G, Liu Y . Hypoxia-inducible factors in cancer stem cells and inflammation. Trends Pharmacol Sci. 2015; 36(6):374-83. PMC: 4461458. DOI: 10.1016/j.tips.2015.03.003. View

12.

Fico F, Bousquenaud M, Ruegg C, Santamaria-Martinez A . Breast Cancer Stem Cells with Tumor- versus Metastasis-Initiating Capacities Are Modulated by TGFBR1 Inhibition. Stem Cell Reports. 2019; 13(1):1-9. PMC: 6626885. DOI: 10.1016/j.stemcr.2019.05.026. View

13.

Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti H . Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature. 2008; 453(7193):410-4. DOI: 10.1038/nature06868. View

14.

Lechertier T, Hodivala-Dilke K . Focal adhesion kinase and tumour angiogenesis. J Pathol. 2011; 226(2):404-12. DOI: 10.1002/path.3018. View

15.

Nallanthighal S, Heiserman J, Cheon D . The Role of the Extracellular Matrix in Cancer Stemness. Front Cell Dev Biol. 2019; 7:86. PMC: 6624409. DOI: 10.3389/fcell.2019.00086. View

16.

de Palma M, Biziato D, Petrova T . Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017; 17(8):457-474. DOI: 10.1038/nrc.2017.51. View

17.

Carnero A, Lleonart M . The hypoxic microenvironment: A determinant of cancer stem cell evolution. Bioessays. 2016; 38 Suppl 1:S65-74. DOI: 10.1002/bies.201670911. View

18.

Carretero R, Sektioglu I, Garbi N, Salgado O, Beckhove P, Hammerling G . Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015; 16(6):609-17. DOI: 10.1038/ni.3159. View

19.

Kim H, Ingham P . The extracellular matrix protein TGFBI promotes myofibril bundling and muscle fibre growth in the zebrafish embryo. Dev Dyn. 2008; 238(1):56-65. DOI: 10.1002/dvdy.21812. View

20.

Pereira B, Chin S, Rueda O, Vollan H, Provenzano E, Bardwell H . The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016; 7:11479. PMC: 4866047. DOI: 10.1038/ncomms11479. View